Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline in diarrhea-predominant IBS
NCT01553591Phase 3Completed
- Sponsor
- Furiex Pharmaceuticals
- Start
- May 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of eluxadoline in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Furiex Pharmaceuticals. Started May 2012; status: completed.
02
Drugs
eluxadoline
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT01553591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553591.